Pfizer stock at EUR 26.17, down 0.83% premarket
Published on 11/13/2026 at 08:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey Points For Investors
- Pfizer develops medicines and vaccines across several therapeutic areas, with oncology, internal medicine, inflammation and immunology among its focus areas.
- Pfizer and Blackstone Life Sciences announced a strategic funding agreement for the company's obesity program on November 11.
- The premarket indication sets a cautious tone before regular US trading begins.
Pfizer stock traded at EUR 26.17 on Lang & Schwarz at 08:39 CET on Friday, November 13, 2026, 0.83 percent below the Xetra close of Thursday, November 12, at EUR 26.39.
Pipeline And Funding In Focus
The premarket indication points to a cautious start for Pfizer shares after a series of company-specific developments in its pharmaceutical pipeline. The move gives investors a fresh reference point ahead of regular US trading, while the broader market will determine whether the early signal persists after the opening bell.
Pfizer describes its business as centered on biopharmaceutical research and the development of medicines and vaccines. Its focus areas include internal medicine, inflammation and immunology, vaccines and oncology, according to the Pfizer website.
On November 11, Pfizer and Blackstone Life Sciences announced a strategic funding agreement for Pfizer's obesity program. The arrangement adds a financing dimension to the company's efforts to advance an experimental obesity treatment, while Pfizer retains control of the program. For investors, the development keeps pipeline execution and the commercial potential of newer medicines at the center of the Pfizer stock story.
The broader US market remains the relevant backdrop for Pfizer stock, with the S&P 500 providing the main index reference for the company's home market.
Further company developments and market analysis are available in more news and analyses on Pfizer stock.
